32264 Long-term efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in pediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) up to 108 weeks

Abstract

Background: About 1% of children and adolescents worldwide are affected by plaque psoriasis (PsO)[1]. We report the long-term efficacy and safety of ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin 17A[1], for moderate-to-severe pediatric PsO from a randomized, double-blind Phase 3 study (IXORA-PEDS [NCT03073200]) up to 108 weeks.